The post Bluerock Value Exchange debuts DIP 7 DST for 1031 investors appeared on BitcoinEthereumNews.com. Accredited real estate investors are being offered newThe post Bluerock Value Exchange debuts DIP 7 DST for 1031 investors appeared on BitcoinEthereumNews.com. Accredited real estate investors are being offered new

Bluerock Value Exchange debuts DIP 7 DST for 1031 investors

For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

Accredited real estate investors are being offered new access to institutional-quality industrial assets through the latest bluerock value exchange program in the 1031 market.

Details of the new DIP 7 industrial portfolio

Bluerock Value Exchange (BVEX) has launched BR Diversified Industrial Portfolio 7, DST (DIP 7), a new 1031 exchange and Delaware Statutory Trust program targeting approximately $60 million in equity from accredited investors. Announced in New York on Feb. 11, 2026, DIP 7 marks BVEX’s 45th individual DST program and its seventh consecutive industrial-focused strategy.

The new all-cash structure is designed as an unlevered DST, which can reduce refinancing risk for investors seeking tax-deferred exchange solutions. Moreover, it aims to appeal to those prioritizing capital preservation and predictable income over aggressive leverage.

DIP 7 consists of a four-state industrial portfolio spanning Alabama (AL), Florida (FL), Missouri (MO) and Virginia (VA). The offering aggregates five separate industrial properties totaling approximately 550,000 square feet, diversified across critical manufacturing, warehouse, distribution and industrial outdoor storage uses.

Tenant profile and lease structure

The properties are reported to be 100% leased to a mix of investment-grade and credit-rated tenants, including publicly traded and privately held companies with global and large national footprints. Moreover, the leases are structured as long-term triple net leases, which typically pass property operating costs to tenants and may support more stable net operating income for investors.

BVEX highlights that this tenant and lease profile is intended to provide steady, income-producing industrial assets within an institutional framework. That said, investors must still evaluate credit quality and lease duration as part of their own due diligence.

Market outlook and industrial sector positioning

According to Josh Hoffman, President of Bluerock Value Exchange, demand from 1031 investors for diversified industrial sector portfolios in high-growth markets has remained strong, particularly when offered in conservative, all-equity structures. He noted that the industrial segment is positioned for potential rent and NOI growth, supported by long-term manufacturing and distribution trends.

Hoffman stated that the firm seeks to preserve capital, deliver income stability and pursue high risk-adjusted returns over a moderate hold period through diversified industrial portfolios such as DIP 7. However, as with all real estate programs, future results will depend on execution, tenant performance and broader market conditions.

BVEX believes that BR Diversified Industrial Portfolio 7 DST represents an attractive opportunity due to its pre-assembled, diversified asset base in high-growth Sunbelt and industrial corridor locations. The DST is designed to provide investors with stable monthly cash flow, alongside the potential for capital appreciation over time.

Rent upside and location characteristics

The properties in DIP 7 are located along major transportation arterials, which can be critical for logistics, distribution and modern supply chain users. Moreover, the portfolio is positioned in what BVEX describes as desirable, high-growth Sunbelt markets and key industrial corridors, where occupier demand for industrial space has been elevated in recent years.

According to CoStar data cited by BVEX, in-place rents at the DIP 7 properties are substantially below current market rates, averaging approximately 25% under prevailing levels. That said, the realization of potential rent growth will depend on lease expirations, market conditions and the sponsor’s asset management strategy.

Bluerock Value Exchange background

With a 20-year track record, Bluerock Value Exchange operates as a national sponsor of syndicated 1031-exchange offerings focused on its Premier Exchange Properties program. The platform seeks to combine stable cash flows with potential value creation through institutional-quality real estate solutions tailored to exchange investors.

Over its history, Bluerock has structured 1031 exchanges totaling more than $3 billion in property value and approximately 15.5 million square feet of real estate. Moreover, the firm has built a presence across multiple U.S. regions, aiming to provide scale and diversification to its investor base.

Additional information on BVEX and its exchange offerings is available at bluerockexchange.com, where prospective investors can review program materials and eligibility criteria.

About Bluerock

Bluerock operates as an institutional alternative asset manager with more than $20 billion of acquired and managed assets. Headquartered in Manhattan, the firm maintains regional offices across the United States, supporting its diversified investment platform.

Bluerock principals collectively bring over 100 years of investing experience and more than $120 billion in real estate and capital markets transaction history. Moreover, they have contributed to the launch of multiple private and public company platforms spanning the alternative investment landscape.

Further details on Bluerock and its broader investment strategies can be found at bluerock.com, where the firm outlines its institutional capabilities and product offerings.

Overall, the DIP 7 launch underscores BVEX’s continued focus on unlevered, income-oriented industrial portfolios for 1031 exchange investors, targeting both current cash flow and longer-term value creation in growth markets.

Source: https://en.cryptonomist.ch/2026/02/11/bluerock-value-exchange-dip7-dst/

Market Opportunity
Daystarter Logo
Daystarter Price(DST)
$0.90742
$0.90742$0.90742
-0.01%
USD
Daystarter (DST) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09